Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX vs FOLFOX + bevacizumab in high-risk stage II colon cancer
2007-001195-36Phase 3Terminated
- Sponsor
- Cancer Trials Ireland
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in colon cancer (2 arms), sponsored by Cancer Trials Ireland. Primary endpoint: Disease-free survival at 3 years. Started Mar 2007; status: terminated.
02
Drugs
bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2007-001195-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001195-36.